Move Comfortably This Summer With The Best Lululemon Align Pieces
This article was created in partnership with lululemon to highlight the brand's Align collection. Shop leggings, tops, bras and more to experience next-level softness and breathability wherever your day may take you.
Staying active during the summer months is easier—and more enjoyable—when you have the right clothes to keep up. The lululemon Align collection is designed to ensure comfort and support with every movement, from morning yoga to afternoon coffee runs to evening strolls. Each piece is crafted with the brand's premium Nulu fabric, which is woven with delicately brushed fine yarns to ensure ultrasoft, lightweight and completely non-constricting coverage.
Shop the best lululemon Align leggings, shorts, bras and more.
The crowd-favorite Align High-Rise Pant is now available without the front-rise seam for an even smoother look and feel. Pair your choice of leggings (or shorts) with a fitted tank, or opt for a chic dress or bodysuit to change up your style. All items ship free, or you can pick up your purchase in store to get it quicker. Read on for the best lululemon Align apparel to shop for your summer workouts, weekend adventures and everything in between.
Align No Line High-Rise Pant
Align High-Rise Pant
Align High-Rise Short
Align Tank Top Light Support
Align Waist-Length Racerback Tank Top
Align V-Neck Bra Light Support
Focuser Scoop-Neck Bra Nulu Light Support
Align Dress
Align High-Rise Skirt
Align Bodysuit
Lululemon
The best-selling Align leggings are now available in a version without the front-rise seam for enhanced smoothness, flexibility and comfort. You can still count on this pant to be just as stretchy and sweat-wicking, and you can choose from either 25- or 28-inch inseam lengths to suit your body type and preferences.
Lululemon
With its buttery-soft feel, a wide no-dig waistband and a hidden waistband pocket, the Align High-Rise Pant is a popular pick for all types of workouts, as well as for running errands, lounging and working from home. If you own a pair already, consider grabbing a new vibrant colorway like Raceway Green—or go for a longer or shorter option with four inseam lengths ranging from 23 to 31 inches.
Lululemon
These shorts are designed to keep you cool during yoga and other mat workouts, but you can also throw them on with a tee or sweatshirt for a casual everyday look. Like the Align leggings, they have a wide, high-rise waistband that won't dig into your skin and a hidden waistband pocket for storing essentials. Choose from 2-inch, 4-inch, 6-inch or 8-inch inseam lengths.
lululemon
This tank has a built-in shelf bra for support during low-impact activities, and it hits right above the waist, making it ideal for pairing with Align leggings or shorts. The fit is meant to be tight but not restrictive; sizes 0 to 14 fit A/B cups, and sizes 16 to 20 fit C/D cups (cups are included, but you can remove them if you prefer).
Lululemon
If you prefer a full-length tank, this racerback-style option is fitted to provide plenty of contouring and support without constricting your movement. Wear it with leggings or shorts for mat workouts, jogs or walks; pair with a skirt for tennis or style under a jean jacket for breezy evening barbecues.
Lululemon
A workout bra that's comfortable enough to wear throughout the day is a staple in any summer closet. Sport this sleek V-neck option on its own for yoga, Pilates or weight training—or put it on under a t-shirt for strolling or running errands.
Lululemon
This bra swaps a deep-V design for a modest scoop neck, and thick straps for thin spaghetti straps—making this lightweight piece a particularly good pick for hot days. Plus, the cups are molded to provide natural shaping, and added stretch means it's quick to slip on and off.
lululemon
A breezy tank dress is ideal for toasty weather, and this one doubles as an option for either fitness or leisure. Built-in shorts ensure coverage and flexibility—with side pockets to stow your essentials and an open-back waistband for more convenient bathroom breaks. The dress includes a shelf bra and is meant to fit tightly for plenty of support as you move.
lululemon
With its smooth, flowy look; shorts liner with pockets; and the same soft no-dig waistband as the Align leggings, this athletic skirt is a multipurpose pick for a variety of summer activities. Choose from 13- or 15-inch lengths (the liner is 3 inches long for all sizes).
lululemon
Make getting ready for yoga class easy with this full-length bodysuit. The built-in bra offers light support, and the streamlined, fitted design is designed to enhance your practice during low-impact activities. Plus, you can keep it on as a stylish statement piece for errands post-workout.
Deciding whether to size up or down when shopping the lululemon Align collection totally depends on your fit and coverage preferences. If you tend to go for a tighter fit when it comes to athleisure, it may make sense to size down—but if you like your workout and lounge clothes to have some breathing room, sizing up is probably your best bet. If you're not sure of your ideal size, you can head to a lululemon store to try items on, or you can order a few different sizes and return what doesn't work within 30 days.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
30 minutes ago
- Bloomberg
Indivior Plans to Cancel London Listing After Moving Primary to US
Indivior Plc said it plans to cancel its secondary listing in London nearly a year after the drugmaker shifted its primary trading to the US, marking the latest departure from the UK's capital markets. The opioid-addiction therapy maker moved its main listing to New York last year in search of more analyst and investor coverage, but had a rocky start amid guidance cuts. It's planning to ditch the secondary trading it had maintained on the London Stock Exchange to better reflect where its revenues come from and eliminate the cost of the secondary listing, given most of its volume and investors are now in the US, according to a statement.
Medscape
30 minutes ago
- Medscape
Centanafadine ‘Clinically Meaningful' for Adult ADHD
LOS ANGELES — The novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine (Otsuka Pharmaceutical Co., Ltd.) is effective and 'clinically meaningful' for adult attention-deficit/hyperactivity disorder (ADHD), new research suggested. In a combined analysis of two phase 3 trials with a total of 859 adults, more patients who received the NDSRI had at least an 18-point improvement at week 6 on the ADHD Investigator Symptom Rating Scale (AISRS) total scores compared with patients on placebo. Additionally, a significantly greater percentage of the active treatment groups showed improvement in the measure's hyperactivity/impulsivity and inattention subscales. Lenard A. Adler, MD But we weren't just interested in statistically significant change but in change 'that means something,' said principal investigator Lenard A. Adler, MD, director of the Adult ADHD program and professor of psychiatry at the New York University (NYU) Grossman School of Medicine, New York City. 'In other words: What do we know is a significant amount of change in patients receiving a compound? That's always a question because we want to get patients well and not just better,' Adler told Medscape Medical News . The findings were presented on May 19 at the American Psychiatric Association (APA) 2025 Annual Meeting. A high-dose, pediatric version of the drug was similarly effective for both children and adolescents in two additional phase 3 trials also presented at the meeting by Adler and colleagues. 'Gives a Benchmark' Centanafadine 'is a triple reuptake inhibitor, so it's not a classical stimulant,' said Adler. 'It's a compound that offers a unique profile.' Investigators pooled data from two identically designed phase 3 trials looking at the drug in patients with a primary diagnosis of ADHD. Together, this included 859 adult patients, with a mean age of 35 years (52% men; 80.3% White). The mean baseline total score on the semi-structured AISRS scale was 38.8 ('moderately ill'), with the mean AISRS inattention score 21.6 ('severely ill') and the mean AISRS hyperactivity/impulsivity score 17.2 ('moderately ill'). The AISRS is conducted as an interview between patient and clinician. 'We also recorded data on clinicians' global impression of severity and global impression of change and then used those as anchors to look at the clinically meaningful within-patient change for the AISRS,' co-investigator Caroline Ward, PhD, director of the Global Clinical Development at Otsuka Pharmaceutical Companies, told Medscape Medical News. All participants were randomly assigned to receive centanafadine at 200 mg (n = 287) or 400 mg (n = 287) or a matching placebo (n = 285). Results showed that the mean change on the AISRS total score at week 6 was −12.1 and −12.5 for the centanafadine 200 mg and 400 mg groups, respectively, vs −8.1 for the placebo group ( P = .002 and .0009). In addition, 24% of the 200 mg group and 25.4% of the 400 mg group achieved an 18-point or greater improvement in AISRS total score from baseline to week 6 compared with 15.4% of the placebo group (ratio of response rate [RR], 1.70; P = .002 and RR, 1.71; P = .001, respectively). A 10-point or greater improvement on the AISRS inattention subscale was achieved by 26.1% of the 200 mg group and 23.3% of the 400 mg group compared with 16.5% of the placebo group (RR, 1.71; P = .001 and RR, 1.45; P = .03, respectively); and an 8-point or greater improvement on the hyperactivity/impulsivity subscale was achieved by 26.5% and 28.6% of the 200 mg and 400 mg groups, respectively, compared with 20% of the placebo group (RR, 1.38; P = .03 and RR, 1.47; P = .01, respectively). The 200 mg and 400 mg groups also reached the 'clinically meaningful within-patient change AISRS threshold' for the first time earlier than the placebo group ( P = .0006 and P < .0001, respectively). Looking at meaningful change 'gives clinicians a benchmark,' said Adler. Pediatric Safety and Efficacy The investigators also presented results from two other randomized phase 3 trials that assessed the drug in children between the ages of 6 and 12 years (n = 480; 58% boys) and adolescents between 13 and 17 years (n = 459; 59% boys). Of these, 77% and 81%, respectively, completed their studies. All were from the United States and Canada. The adolescents received high-dose centanafadine (328.8 mg once daily), low-dose centanafadine (164.4 mg once daily), or placebo for 6 weeks. The children received a placebo or a high or low dose of centanafadine, with doses based on their weight. A larger number of children who received high-dose centanafadine had an 18-point or greater improvement at week 6 on the ADHD Rating Scale–5 (ADHD-RS-5) total score compared with the children who received placebo (34.5% vs 23.3%; P = .03), with even stronger effects found in the adolescents (47.7% vs 31.7%; P = .004). A greater number of the high-dose active treatment group vs the placebo group also had at least a 10-point improvement in ADHD-RS-5 inattention subscale scores (children, P = .03; adolescents, P = .003) and at least an 8-point improvement in hyperactivity/impulsivity subscale scores ( P = .04 and .03, respectively). In addition, the mean change from baseline to week 6 on the ADHD-RS-5 total score was −16.3 for the children receiving the high-dose drug vs −10.8 for those receiving placebo ( P = .0008) and was −18.5 vs −14.2 in the adolescents ( P = .0006). When assessing caregiver-rated improvements, investigators found that a greater number of children and adolescents receiving high-dose centanafadine vs placebo achieved at least a 14-point improvement on the Conners 3–Parent Short Inattention T-scores ( P = .02 and .001, respectively) and at least a 13-point improvement on the Conners 3–Parent Short Hyperactivity/Impulsivity T-scores ( P = .02 and .007, respectively). Most treatment-emergent adverse events were deemed to be mild to moderate. The most common adverse events in the high-dose centanafadine group were decreased appetite and rash in the children and decreased appetite, rash, nausea, and headache in the adolescents. Ward reported that data from these studies, along with some they conducted previously and some that are ongoing, will be part of a package they're preparing to send to the US Food and Drug Administration in the near future. Altogether, 'it tells a nice story,' she said. Real-World Data Commenting for Medscape Medical News, Soonjo Hwang, MD, associate professor of psychiatry at the University of Nebraska Medical Center, Omaha, Nebraska, noted that among treatments already available for ADHD, the most well-known are stimulant medications, which 'are purely' dopaminergic reuptake inhibitors. Soonjo Hwang, MD 'That said, norepinephrine, dopamine, and serotonin have a close relationship with each other in the brain. So, if you inhibit one, it will have an impact on the others as well,' said Hwang, who was not involved with the new research. He pointed out that centanafadine has a similar profile to other medication groups, such as antidepressants, that have been assessed previously for ADHD. 'In terms of the mechanism, it's similar to some we've had in the past. Still, it is really important for us to have new tools to treat this disorder because we currently have limited options,' Hwang said. He noted that being 'clinically meaningful' is a concept worth thinking about. 'This was a randomized-controlled clinical trial that [focused] towards more real-world data. And it's important to have data on how the medication performs in a real-world situation before launching it to market,' he said. Hwang added that he'd also like to know, moving forward, how well the medication works in patients with comorbidities, which is common in those with ADHD.
Yahoo
36 minutes ago
- Yahoo
11 stabbed at Salem, Oregon mission that aids homeless people
Eleven people were stabbed Sunday evening at a Salem, Oregon mission that aids homeless people and a male suspect was in custody, police said. All the victims were brought to a local hospital with "varying types of injuries," police added. It happened at the Union Gospel Mission, which helps "men, women, and children break free from homelessness through the transforming grace of Jesus Christ," according to its website. There was no word on what prompted the attack or the suspect's identity. The wonderfully weird world of artist Luigi Serafini Fans turn out for estate sale at home of Tom Petty Dozens killed in attack near Gaza aid delivery point, witnesses blame IDF, Israel denies involvement
